Last reviewed · How we verify
[Ga-68]PSMA
[Ga-68]PSMA is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable visualization and localization of tumors.
[Ga-68]PSMA is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable visualization and localization of tumors. Used for PET imaging of PSMA-positive lesions in men with prostate cancer, Detection and staging of metastatic prostate cancer.
At a glance
| Generic name | [Ga-68]PSMA |
|---|---|
| Sponsor | Norbert Avril, M.D. |
| Drug class | PET imaging agent / radiopharmaceutical |
| Target | PSMA (prostate-specific membrane antigen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Gallium-68 is a positron-emitting radioisotope conjugated to a PSMA-targeting ligand that accumulates in PSMA-expressing prostate cancer cells. When injected intravenously, the radiotracer localizes to primary tumors and metastases, allowing PET imaging to detect and stage prostate cancer with high sensitivity and specificity. This enables clinicians to identify disease burden and guide treatment decisions.
Approved indications
- PET imaging of PSMA-positive lesions in men with prostate cancer
- Detection and staging of metastatic prostate cancer
Common side effects
- Injection site reactions
- Radiation exposure (inherent to PET imaging)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [Ga-68]PSMA CI brief — competitive landscape report
- [Ga-68]PSMA updates RSS · CI watch RSS
- Norbert Avril, M.D. portfolio CI